EP0377518A2 — Sustained release pharmaceutical composition
Assigned to Mayne Pharma International Pty Ltd · Expires 1990-07-11 · 36y expired
What this patent protects
A sustained release pharmaceutical pellet composition suitable for treating pain-associated conditions in patients comprises a core element including at least one active ingredient of high solubility; and a core coating for the core element which is partially soluble at a highly …
USPTO Abstract
A sustained release pharmaceutical pellet composition suitable for treating pain-associated conditions in patients comprises a core element including at least one active ingredient of high solubility; and a core coating for the core element which is partially soluble at a highly acidic pH to provide a slow rate of release of active ingredient e.g a morphine compound, and wherein the active ingredient is available for absorption at a relatively constant faster rate in the intestine over an extended period of time, such that blood levels of active ingredient are maintained with the therapeutic range over an extended period of time.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.